

# WISCONSIN Diabetes Data & Forecasts

State Total Population Forecasts	2015	2020	2025	2030
Entire Population	5,882,800	6,005,000	6,088,400	6,150,800
Prediabetes	1,610,200	1,697,900	1,773,000	1,793,500
Diagnosed diabetes	435,500	526,500	600,200	654,700
Undiagnosed diabetes	165,800	190,400	205,900	212,800
Total with diabetes (diagnosed and undiagnosed)	601,300	716,900	806,100	867,500
<b>Complications:</b>				
Visual impairment	71,400	83,800	92,700	98,200
Renal failure	1,040	1,210	1,330	1,400
Leg amputations	900	1,000	1,050	1,050
Annual deaths attributable to diabetes	4,690	5,410	5,860	6,050
Total annual cost (2015 dollars)	\$6.9 B	\$8.2 B	\$9.2 B	\$9.8 B
Annual medical costs	\$5.3 B	\$6.3 B	\$7.1 B	\$7.5 B
Annual nonmedical costs	\$1.6 B	\$1.9 B	\$2.1 B	\$2.3 B

State Senior Population Forecasts	2015	2020	2025	2030
Population 65 and older	881,700	1,025,500	1,183,600	1,312,200
Prediabetes	449,700	523,000	603,600	669,200
Diagnosed diabetes	166,700	193,800	223,700	248,000
Undiagnosed diabetes	61,700	71,800	82,900	91,900
Total with diabetes (diagnosed and undiagnosed)	228,400	265,600	306,600	339,900
<b>Complications:</b>				
Visual impairment	31,200	35,300	39,700	42,900
Renal failure	510	580	640	690
Leg amputations	380	410	440	450
Annual deaths attributable to diabetes	3,240	3,630	3,810	3,810
Total annual cost (2015 dollars)	\$2.9 B	\$3.4 B	\$3.9 B	\$4.3 B
Annual medical costs	\$2.7 B	\$3.2 B	\$3.7 B	\$4.1 B
Annual nonmedical costs	\$0.2 B	\$0.2 B	\$0.2 B	\$0.2 B

These forecasts are based on the latest available national diabetes data, including U.S Census Bureau population projections, the CDC National Diabetes Statistics Report, 2014, CDC diabetes morbidity trend reports, CDC's latest diabetes prevalence projections to 2050 and Dall, et al. "The Economic Burden of Elevated Blood Glucose Levels in 2012: Diagnosed and Undiagnosed Diabetes, Gestational Diabetes Mellitus, and Prediabetes," *Diabetes Care* 2014;37:3172-3179. These forecasts assume a steady, but conservative, reduction in the number of people with complications due to better awareness of the risks of diabetes, earlier screening and intervention, and more effective therapies.

For details and references on the Institute for Alternative Futures Diabetes 2030 Forecasting Model Methodology, visit [www.altfutures.org/diabetes2030](http://www.altfutures.org/diabetes2030).

Research funded by Novo Nordisk Inc.